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tion of surveillance cultures found only one patient developed colo-
nization with VRE after AP. Two patients had C. difﬁcile infection and
one patient C. glabrata in the urine during their AP. Data collection
remains ongoing and a comparison to historical infection data will be
presented.
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BACKGROUND
Hypothermia, which is a common side effect of apheresis, has
negative effects on the donor’s and patient’s body functions.
The aim of this study was to examine the effects of warming
methods on plateletpheresis donors’ temperature, cardiac and im-
munologic function.
STUDY DESIGN AND METHODS
50 plateletpheresis donors were randomly assigned to control
group(n25) or warming group(n25) with an air warmer and a
blood warmer during plateletpheresis. The effects of the treatment
were examined by comparing body temperature, heart rate, blood
pressure, Holter EKG pattern, serum Interleukin-1	(IL-1	), Inter-
leukin-2(IL-2), tumor necrosis factor- (TNF-) concentration,
white blood count, white blood fraction, platelet count by point of
time between the two groups.
RESULTS
Tympanic temperature decreased less in the treatment group than
in the control group. Systolic blood pressure decreased in both
groups, but the difference was not signiﬁcant. However, the decrease
of diastolic blood pressure was signiﬁcantly less in the treatment group
than in the control group. As for cardiac function, the frequency of
abnormal pulsation was generally lower in the treatment group, but
the difference was not signiﬁcant. IL-1	was not signiﬁcantly different
between the two groups. IL-2 and TNF- decreased signiﬁcantly
after plateletpheresis in the control group.
CONCLUSION
To reduce the risk of serious side effects, more careful monitor-
ing and intervention for change of cardiac & immunologic func-
tion is required in apheresis.
And warming methods can maintain the balance of tympanic
temperature, IL-2 and TNF-, warming methods is considered
more useful in patients of therapeutic apheresis.
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SAMPLE SIZE REQUIREMENTS FOR STUDIES IN WHICH TIME-TO-NEU-
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When planning clinical trials in which time-to-neutrophil-engraft-
ment is the primary statistical endpoint, it is critical to utilize an
appropriate sample size. Insufﬁcient sample size can result in a failure
to identify interventions that could have a meaningful effect on neu-
trophil recovery, whereas overly large sample size can lead to excessive
study cost and duration. To our knowledge, all currently available
software packages for calculating sample size base their estimates on
theoretical mathematical distributions rather than on the uniquely
distributed time-to-event proﬁles that characterize actual neutrophil
recovery following BMT. In order to address these issues, we have
developed a SAS-based clinical trials simulator in which the time-to-
engraftment probabilities are based directly on observed time-to-
engraftment distributions in actual cohorts of patients. By conducting
thousands of simulated trials, the power and sample size requirements
for detecting speciﬁed differences in engraftment time at a statistically
signiﬁcant level versus any desired reference population of patients
can be accurately estimated. Our initial series of simulations were
based on the time-to-engraftment distribution observed in a series of
actual patients undergoing melphalan-conditioned, ﬁlgrastim-sup-
ported autologous peripheral blood stem cell transplantation for mul-
tiple myeloma, and involved approximately 1.4 million simulated
patients enrolled on approximately 30,000 simulated randomized tri-
als. In the above-mentioned patient population, in which the neutro-
phil engraftment times are very tightly clustered around the mean, the
model estimated that only 37 patients would need to be randomized
to yield an 80% probability of detecting a 1-day difference in the
median neutrophil engraftment time at the p 0.05 signiﬁcance level,
and that only 48 patients would need to be randomized to yield a 90%
probability. Subsequent simulations will illustrate that sample size
requirements will be higher in patient populations in which the dis-
persion in neutrophil engraftment times is wider.
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Background: HSCT recipients often receive the immunosup-
pressants CsA or TAC for GVHD concomitantly with an azole for
prevention of invasive fungal infection (IFI). As CsA and TAC are
metabolized by the cytochrome P450 enzyme, CYP3A4, and azoles
are CYP3A4 inhibitors, potential drug interactions are a concern.
CsA and TAC dose changes were analyzed in a trial of POS vs
FLU as IFI prophylaxis in HSCT recipients with GVHD.
Methods: 600 patients were randomized to receive POS (200 mg
po t.i.d., n301) or FLU (400 mg po q.d., n299) for up to 16 weeks.
A sample of subjects randomized at 3 major enrolling centers was
selected for examination of CsA and TAC dose adjustments at initi-
ation of prophylaxis and after 2 weeks of treatment, because CsA and
TAC levels typically decrease early during coadministration with
azoles.
Results: In the total study, 206 POS and 213 FLU patients
received CsA, while 47 POS and 50 FLU patients received TAC.
Therapeutic drug monitoring records were reviewed for 49 sub-
jects. CsA plasma levels were determined in 19 POS and 19 FLU
patients, and TAC plasma levels were determined in 7 POS and 5
FLU patients. Changes in CsA levels-to-dose ratio (C/D) were
comparable in both groups by week 2, increasing by 17% in POS
patients and 14% in FLU patients (table). Despite dosing adjust-
ments in both groups, CsA plasma levels decreased to a greater
extent in the FLU group. By week 2, TAC C/D and plasma levels
increased in the POS group but decreased in the FLU group.
Conclusion: These data suggest that POS and FLU have a similar
impact on CsA levels as shown by C/D ratio changes. CsA dose
reductions of approximately 30% to 45% upon initiation of prophy-
laxis are recommended in order to maintain effective drug levels
within the therapeutic range. Numbers of observations for TAC in
both groups were too low to draw any conclusions. Monitoring of
CsA or TAC levels during coadministration with an azole is recom-
mended.
POS FLU
Baseline Week 2 Change Baseline Week 2 Change
CsA n  19 n  19 n  19 n  19
Mean C/D 0.93 1.09 17% 1.25 1.43 14%
Mean plasma levels*
(ng/mL) 351.0 314.2 -10% 386.5 294.6 -24%
Mean dosing (mg/d) 570.9 307.8 -46% 365.8 263.2 -28%
TAC n  7 n  6 n  5 n  4
Mean C/D 3.43 4.39 28% 7.68 6.51 -15%
Mean plasma levels*
(ng/mL) 10.6 12.2 15% 14.9 13.8 -7%
Mean dosing (mg/d) 15.3 4.0 -74% 2.9 3.3 14%
*Highest value within interval
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